Bajaj Finserv Small Cap Fund
The scheme seeks to generate long term capital appreciation by investing in equity and equity related securities of small cap companies.
Growthvine rating: 2/5 — ranked #25 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹11.26 (as of 2026-08-21) |
|---|
| AUM | ₹2,364 Cr |
|---|
| Expense ratio | 1.72% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nimesh Chandan |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 6 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -16.98% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 115.4% of NIFTY Smallcap 250's upside and 101.3% of its downside.
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 11.0% |
|---|
| Small cap | 89.0% |
|---|
Concentration
| Top 5 holdings | 16.0% |
|---|
| Top 10 holdings | 28.0% |
|---|
| Total holdings | 94 |
|---|
| Index overlap | 19.6% |
|---|
| Active share | 80.4% |
|---|
Top holdings
- RUBICON RESEARCH LIMITED — 4.1%
- S.J.S. Enterprises Limited — 3.2%
- Zydus Wellness Limited — 3.0%
- Neuland Laboratories Limited. — 3.0%
- Welspun Corp Limited — 2.7%
- Schaeffler India Limited — 2.7%
- Federal Bank Ltd. — 2.5%
- ANGEL ONE LIMITED — 2.4%
- Timken India Ltd — 2.4%
- PIRAMAL PHARMA LIMITED — 2.1%
Top sectors
- Industrial Products — 15.2%
- Pharma & Biotech — 12.7%
- Banking & Financial — 9.5%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 17.5% | Q2 | #11 of 34 |